Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting now · Phase 3

Conditions studied: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma

In brief

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Key facts

Study ID

NCT07252232

Run by

Revolution Medicines, Inc.

People needed

500

Starts

2025-12-15

Expected to finish

2030-07-10

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old and has provided informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.
• Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.
• Must have completed most recent treatment within the past 12 weeks.
• Adequate organ function (bone marrow, liver, kidney, coagulation).
• Documented RAS mutation status.
• Able to take oral medications.

You may not qualify if…

• Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
• Any conditions that may affect the ability to take or absorb study drug.
• Major surgery within 28 days prior to randomization.
• Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Where it is running

• UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
• Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
• University of California, Los Angeles — Los Angeles, California, United States (enrolling)
• Stanford Cancer Institute — Palo Alto, California, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• Rocky Mountain Cancer Centers, LLP — Lakewood, Colorado, United States (enrolling)
• Hartford Healthcare — Hartford, Connecticut, United States (enrolling)
• Mayo Clinic — Jacksonville, Florida, United States (enrolling)
• University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
• Florida Cancer Specialists — St. Petersburg, Florida, United States (enrolling)
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
• Community Health Network — Indianapolis, Indiana, United States (enrolling)
• University of Kansas Medical Center Research Institute, Inc. — Lawrence, Kansas, United States (enrolling)
• Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States (enrolling)
• Saint Luke's Cancer Institute — Kansas City, Missouri, United States (enrolling)
• University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States (enrolling)
• Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center — New York, New York, United States (enrolling)
• Columbia University Medical Center — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Duke Cancer Center — Durham, North Carolina, United States (enrolling)
• Mayo Clinic — Phoenix, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.